Stephen A. Cannistra
Beth Israel Deaconess Medical Center · 98 works · 7,491 citations · h-index 37
Top works
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression
- Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer
- Location of BRCA1 in Human Breast and Ovarian Cancer Cells
- Granulosa Cell Tumor of the Ovary
- Cancer of the Uterine Cervix
- Cancer of the Ovary
- Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- Frequent Loss of PTEN Expression Is Linked to Elevated Phosphorylated Akt Levels, but Not Associated with p27 and Cyclin D1 Expression, in Primary Epithelial Ovarian Carcinomas
- BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway
- Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer
- The Ethics of Early Stopping Rules: Who Is Protecting Whom?
- Phase II Trials in Journal of Clinical Oncology
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity
- β1-Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro
- Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
- Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
- Unique Gene Expression Profile Based on Pathologic Response in Epithelial Ovarian Cancer
- Advances in the management of epithelial ovarian cancer.
- Is There a “Best” Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer?